Bristol-Myers Squibb- High Dividend, Zero Growth

Jason Chew With a 5% dividend, Bristol-Myers Squibb provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero interest rate environment. There are however, a couple hiccups for investors to be aware of- Bristol is set to lose patent protection on its best-selling […]

Anthera Pharmaceuticals- IPO, What’s Next?

Jason Chew After the 2000 bubble and crash, the biotech IPO has finally begun to crack open a bit. First, Ironwood tested the waters in February with the largest IPO in two years. Anthera soon followed March 4, raising just $37.1 million after cutting its IPO price from the $13-$15 range to just $7. An […]

Cubist vs. Hatch-Waxman

In 2003, Cubist was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the stock doubled from about $10 to $20. The stock has languished in the $20 trading range for nearly five years now. There have been some […]

Targacept- Ready to Take Off

Jason Chew Targacept is a company focused on CNS diseases and disorders, targeting Neuronal Nicotinic Receptors (NNRs). As a company spun off from R.J Reynolds and still located in Winston-Salem, it knows a thing or two about this subject. NNRs are ion channels that open in response to the binding of the neurotransmitter acetylcholine allowing […]

Curis Drug GDC-0449 Fails Colorectal Trial

Jason Chew Curis released results today for its hedghog pathway inhibitor GDC-0449 in a pivotal Phase II colorectal trial run by Roche. The company said its drug failed to extend the time of disease progression or death in patients with metastatic colorectal cancer. Curis stock plunged from yesterday’s close of $3.26 to $1.69, a 48% drop. This […]

Ariad is Set For Success

Jason Chew For years, much of Ariad’s value had been tied to its mTOR inhibitor, Ridaforolimus. Ridaforolimus is an orally bio-available analog of Rapamycin- an immunosuppresent discovered decades ago- the “R” in mTOR. Thus far, there are two other analogs, or Rapalogs, as they are called, approved in oncology indications ahead of Ridaforolimus, the first-to-market […]

Genomic Health- Possible Takeover Candidate

Jason Chew Genomic Health is a pure-play oncology in-vitro diagnostics company with approved products and a pipeline to drive future growth. It fits in well with the growing importance of personalized medicine in the pharmaceutical industry. Personalized medicine is comprised of two parts- the drug, and the diagnostic, a combination sometimes referred to as Dx/Rx. […]

Celldex Sets it Straight at ASCO

After Celldex’s flubbed pre-ASCO abstract release led investor to question interim Phase II data for its cancer vaccine CDX-110 (PF-04948568), also with the generic name Rindopepimut, they made sure to get things straight at ASCO. As a reminder, the abstract stated 70% of patients on drug were alive and progression free at 5.5 months. This […]

Vivus Has a Hit in Qnexa

Obesity has a high prevalence in the US and is now frequently cited as being a national health issue. It is on the rise in almost every industrialized and some industrializing nations. There are currently no blockbuster weight loss drugs due to lack of efficacy, though many have failed due to unwanted side effects. Some […]

Investment Opportunities in Women’s Health

The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has completed data collection for it’s 2186-patient study of Pristiq for the treatment of vasomotor symptoms, more commonly known as hot flashes. Wyeth, now part of […]

Roche- Leading the Way in Personalized Medicine

(Featured in TheBigRedBiotechBlog) This Swiss pharma is the third largest pharmaceutical company both by revenue and market cap. It is one of the fastest growing companies in its peer group, with sales growth of 7% in 2009. This compares to approximately 4% YoY growth for Pfizer, Sanofi-Aventis, and Johnson & Johnson. With the purchase of […]

Incyte Pharmaceuticals: JAK it Up

Incyte Pharmaceuticals: JAK it Up Incyte Pharmaceuticals has one of the most promising pipelines in the small to mid-cap space. It has two very promising compounds in development, INCB18424 for the treatment of Myelofibrosis (MF), a disease classified under the Myeloproliferative disorders (MPD) family, and other oncology indications, and INCB28050 for the treatment of Rheumatoid […]

Biotech’s One-Trick Pony

The One-Trick Pony We’ve heard this many times- never bet on that one-trick pony. Risky bet. You’ll lose your shirt. So what does this one-trick pony thing look like? What should we be looking out for? Where do we find this three-horned beast? But seriously, what defines a biotech as a one-trick pony? Here I […]

The Promise Behind Celldex- ASCO 2010

The Promise Behind Celldex Celldex shares climbed steadily in the months leading up to the release of its ASCO abstracts, rising from $4.71 at the start of the year and hitting a high of $9.43 on May 18. Shares 9% the day the abstracts were released on May 21, closing at $6.97. Share prices have […]

Bionovo: novel approach, challenges ahead, but poised to move higher

The Women’s Health Initiative (WHI), a study that demonstrated several lethal side-effects of hormone replacement therapy (HRT), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the unique market demand created by the drop in hormone sales. Although several therapies have advanced to late-stage clinical studies, few represent a truly novel approach. […]

Weight loss, as easy as taking a Qnexa pill

Vivus Pharmaceuticals shocked the health-care industry earlier this year when it announced positive phase III results for it’s new obesity miracle drug. The drug, dubbed Qnexa, is a combination of two, already approved therapies, phentermine and topiramate. Qnexa, combines phentermine, the stimulant that boost the metabolism, with topiramate, an anti-convulsant that also interferes with binge-eating […]

Warner Chilcott to devour Proctor & Gamble drug unit

Pharmaceutical M&A is still robust. Rumors are spreading that Warner Chilcott (NASDAQ:WCRX) will purchase Proctor & Gamble’s (NYSE:PG) prescription drug unit as early as tomorrow. The price tag is rumored to be around $3 Billion USD. If the deal is completed, Warner Chilcott will double it’s annual revenue, making it a resounding force in the […]